Clinical Trial Update: A Clinical Study to Evaluate the Pharmacokinetics and the Absolute Bioavailability of SRT2104 Given as a 250mg Oral Suspension and Intravenous Microdose of 100 µg Carbon-14 Radio-labeled SRT2104 in Healthy Male Subjects [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study in healthy male volunteers to determine the pharmacokinetics and absolute oral bioavailability of SRT2104 using a 250 mg oral susp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• SRT2104 (SRT2104)

Snippet

Sponsor: Sirtris, a GSK Company | Conditions: Diabetes Mellitus, Type 2 | Phase 1 | Status: COMPLETED